C ontrast-induced acute kidney injury (CI-AKI) is a common complication after procedures requiring contrast media, responsible for 11% of in-hospital acute kidney injury cases. 1, 2 The risk of CI-AKI is independently associated with baseline comorbidities, such as chronic kidney disease (CKD), impaired left ventricular systolic function, diabetes mellitus, anemia, and hemodynamic instability. 3 Although CI-AKI has been explored in several studies, there are few recent and large substudies examining patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).
Contrast-Induced AKI and Adverse Outcomes increased incidence of CI-AKI in ACS. 4 Although CI-AKI occurs in <3.5% of low-risk patients undergoing elective procedure, 5, 6 the incidence dramatically increases to 15% to 19% in ACS. 7, 8 Similarly, bleeding events after PCI for ACS are more common compared with elective procedures because of the higher use of anticoagulant and antithrombotic medications. 9, 10 The association between increased bleeding events and CI-AKI has not been extensively explored, particularly in the context of ACS, which may provide additive risk to the incidence of ischemic and hemorrhagic events. [11] [12] [13] The aim of this patient-level pooled analysis was to describe the predictors and impact of CI-AKI in a large cohort of patients undergoing PCI in the context of ACS.
Methods

Trial Design
This study is a pooled analysis of patients who underwent PCI for ACS in the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. The study design and primary outcomes of these 2 randomized trials have been described in detail previously. 14, 15 In the HORIZONS-AMI trial, 3602 patients admitted with STEMI presenting within 12 hours after symptom onset underwent randomization (1:1) before primary PCI to unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) or bivalirudin; patients in the bivalirudin group could receive bailout GPI. Aspirin and clopidogrel were administered before catheterization and continued for a minimum of 6 months (with a recommended duration of 1 year or longer). After coronary angiography, 3006 patients were randomized (3:1) to Taxus Express 2 (Boston Scientific, Natick, MA), paclitaxeleluting stents or to Express 2 (Boston Scientific), the identic bare metal version of the stent.
In the ACUITY trial, 13 819 patients with unstable angina or non-STEMI were randomly assigned (1:1:1) before coronary angiography to bivalirudin alone, bivalirudin plus a GPI, or heparin (either unfractionated or low molecular weight) plus a GPI. After the diagnostic procedure, patients were triaged to PCI, coronary artery bypass grafting, or medical management at the discretion of individual operators. Aspirin and clopidogrel were started before catheterization and continued for at least 1 year.
After excluding patients triaged to coronary artery bypass grafting or medical therapy, PCI patients included in this pooled analysis were grouped according to development of postprocedural CI-AKI and adverse events at 30 days and 1 year were compared. Both trials were approved by the Institutional Review Committee at each participating center, and subjects gave written informed consent.
End Point Definitions
An independent clinical events committee blinded to randomization adjudicated all primary end points. Death from cardiac causes was defined as death because of acute myocardial infarction, cardiac perforation or pericardial tamponade, arrhythmia or conduction abnormality, stroke, procedural complications, or any death for which a cardiac cause could not be ruled out. Noncardiac death, MI (periprocedural, reinfarction, and spontaneous), stent thrombosis (definite/probable), and ischemia-driven target lesion revascularization (TLR) and target vessel revascularization were defined according to the Academic Research Consortium. 16 Major adverse cardiovascular events (MACEs) were defined as the composite of death, reinfarction, or target vessel revascularization. Net adverse clinical events were defined as MACE or major bleeding.
As per trial definitions, major bleeding was defined as any intracranial or intraocular bleeding, access site hemorrhage requiring intervention, hematoma with diameter ≥5 cm, hemoglobin drop ≥4 g/ dL without overt bleeding source or ≥3 g/dL with a bleeding source, reoperation for bleeding, or blood product transfusion. Bleeding events were stratified in relation to site (gastrointestinal, genitourinary, or pulmonary), clinical expressions (gingival bleed, hematemesis, melena, pharyngeal bleed; epistaxis, hemoptysis, pulmonary parenchymal bleed; and gross hematuria), and relationship with catheterization procedure (access site hemorrhage, access site bleeding ≥30 minutes, hematoma diameter <5 cm, hematoma diameter ≥5 cm). Bleeding events were also assessed using the Thrombolysis in Myocardial Infarction bleeding scale. 17 For the objective of this study, CI-AKI was defined as an absolute increase of serum creatinine ≥0.5 mg/dL or relative increase ≥25% from baseline value within the first 72 hours of intervention.
Statistical Analysis
Categorical variables are presented as percentages and were compared using the χ 2 test or Fisher exact test, as appropriate. Continuous variables are presented as a mean with SD or as a median with interquartile range [Q1, Q3] and were compared using the Student t test or Mann-Whitney U test, respectively. Outcomes were estimated with the Kaplan-Meier method and compared with the log-rank test. Multivariable hazard regression analysis was performed to identify predictors of CI-AKI. Variable selection was based on both clinical and statistical significance. A stepwise logistic regression model with an entry and exit level of significance of 0.1 was used to identify independent predictors of CI-AKI. Adding CI-AKI to the same set of variables, multivariable Cox's proportional hazard regression analysis was used to identify independent predictors of death, MI, Q-wave MI, ST, TLR, and MACE at 1 year. We used a stepwise regression analyses with an entry and exit level of significance of 0.1 also to identify independent predictors for 30-day major bleeding events. Moreover, the possible association between CI-AKI and bleeding was reexamined in a landmark analysis for 30-day bleeding events starting from the third postprocedural day. Results are presented as hazard ratio with 95% confidence interval. A P <0.05 was considered significant for all analyses. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
WHAT IS KNOWN
• Contrast-induced acute kidney injury (CI-AKI) is a common complication after coronary artery angiography and percutaneous coronary intervention.
• There are few recent and large studies exploring the impact of CI-AKI in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
WHAT THE STUDY ADDS
• This patient-level pooled analysis from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials extensively describes the effects of CI-AKI on short-and long-term cardiovascular outcomes in a contemporary population of patients with acute coronary syndrome undergoing percutaneous coronary intervention.
• CI-AKI is a strong-independent predictor of adverse cardiovascular events at 1 year.
• CI-AKI significantly amplifies the risk of postprocedural bleeding events.
Results
A total of 9512 patients who received PCI in the HORIZONS-AMI and ACUITY trials with available serial serum creatinine measurements were included in this patient-level pooled analysis; of these patients, 1212 (12.7%) developed CI-AKI. Baseline clinical characteristics are presented in Table 1 . Patients who developed CI-AKI were older, and more commonly female, diabetic, and hypertensive, and were more likely to have a history of CKD or cerebrovascular events.
In contrast, patients who developed CI-AKI were older, more commonly female, diabetic, hypertensive, and were more likely to have a history of CKD or cerebrovascular events. Baseline hematocrit was lower in the group that developed CI-AKI, whereas CK-MB levels were higher.
Angiographic and procedural features ( Table 2) suggest that patients with CI-AKI more commonly had complex coronary lesions. Patients with CI-AKI tended to have a worse hemodynamic pattern with higher rates of vessel total (Thrombolysis in Myocardial Infarction 0) or functional occlusion (Thrombolysis in Myocardial Infarction I) both before and after procedure. There were no differences in antithrombotic regimens between groups. Contrast volume was significantly greater in patients with CI-AKI. However, there was no difference in terms of iso-osmolar contrast media use.
After multivariable analysis (Table 3) , advanced CKD, diabetes mellitus, contrast volume, age, left ventricular ejection fraction, baseline hemoglobin, GPI use, previous PCI, and previous coronary artery bypass grafting were independently associated with CI-AKI.
Clinical Outcomes
Clinical outcomes are presented in Table 4 . Patients who developed CI-AKI experienced higher rates of 30-day and 1-year mortality, both cardiac and noncardiac. MI at 30 days was significantly higher in the CI-AKI group. At 1 year, MI was numerically higher but the difference was not statistically significant; however, Q-wave MI at 1 year remained more frequent in patients with CI-AKI. Definite or probable ST was significantly higher in CI-AKI, both in the short-and long-term. Similarly, TLR, target vessel revascularization, and MACE rates at 30 days and 1 year were significantly greater in the CI-AKI group. Rates of 30-day net adverse clinical events were also higher in patients with CI-AKI. Figure 1 depicts After multivariable analysis, CI-AKI was found to be the strongest independent predictor of 1-year death, Q-wave MI, and definite/probable ST and among the strongest independent predictors of TLR and MACE (Table 5 ).
Bleeding Events
Bleeding events at 30-day follow-up were significantly higher in the CI-AKI group (Table 6; Figure 2 ); this result remained unchanged when analyzed using the Thrombolysis in Myocardial Infarction bleeding score. Both access site and nonaccess site major bleeding were significantly higher in patients with CI-AKI. Patients with CI-AKI had significantly higher rates of access site hematomas (both ≥5 cm and <5 cm in diameter). In addition, there was a rise in risk of hemoglobin drop ≥4.0 g/dL without and ≥3.0 g/dL with an overt bleed source, blood product transfusion, and retroperitoneal bleeding. Almost all nonaccess site bleed types were increased postprocedurally in patients with CI-AKI. This was particularly evident by the increase in risk of gross hematuria, melena, and pharyngeal bleeding 30 days after procedure. Other hemorrhagic events which were significantly more common in the CI-AKI group included hemoptysis, epistaxis, and pulmonary parenchymal bleeding.
To evaluate bleeding events specifically occurring after CI-AKI development and to minimize possible non-CI-AKI-related periprocedural bleeding, we performed a landmark analysis for 30-day bleeding starting from the third Potential covariables included in model: age, sex, diabetes mellitus, creatinine clearance <60 mL/min, contrast volume (per 100 mL increase), randomization to bivalirudin, randomization to glycoprotein IIb/IIIa inhibitor, history of hypertension, hyperlipidemia, anemia, previous percutaneous coronary intervention, and previous coronary artery bypass grafting. All the possible interactions between the variables were assessed using a separate model with the main effects and an interaction. All the main effects and the significant interactions were kept in the multivariable model. The table shows results of the significant variables in the final model. Values are % (n). CI-AKI indicates contrast-induced acute kidney injury. Contrast-Induced AKI and Adverse Outcomes postprocedural day. This landmark analysis showed that bleeding events between 3 and 30 days from the procedure remained significantly higher in patients with CI-AKI (6.5% versus 1.9%; hazard ratio, 3.59; 95% confidence interval, 2.70-4.76; P<0.001; Figure 2 ). After multivariable adjustment, CI-AKI remained strongly associated with 30-day major bleeding, resulting in a >2-fold risk (Figure 3 ).
Discussion
The principal findings of this patient-level pooled analysis of the large-scale HORIZONS-AMI and ACUITY trials are as follows: (1) rates of CI-AKI were substantial after PCI for non-ST-segment-elevation ACS and STEMI (12.7%); (2) several well-established predictors were confirmed to be independently associated with CI-AKI; (3) CI-AKI was independently associated with short-and long-term risk for death and MACE; and (4) CI-AKI was also independently associated with 30-day major bleeding. The interpretation of the increased morbidity and mortality observed after CI-AKI development is challenging because of the correlation between preexisting clinical variables associated with both CI-AKI and adverse clinical outcomes. In agreement with previous studies, we found that patients who developed CI-AKI had a worse cardiovascular risk profile and a higher prevalence of comorbidities. After multivariable analysis, established risk factors for CI-AKI, such as CKD, diabetes mellitus, and increased contrast volume, were found to be independently associated with CI-AKI in this large cohort of ACS patients. Patients with previous myocardial revascularization, both PCI and coronary artery bypass grafting, had a reduced risk of CI-AKI. This may be an expression of the lower number of untreated lesions requiring PCI in these patients.
However, we also sought to determine independent longterm risk factors for MACE. After multivariable analysis, we identified CI-AKI as the strongest factor associated with death and the second strongest factor correlated with MACE at 1 year. Other significant predictors were previous renal dysfunction and diabetes mellitus. These results suggest that, although patients who develop CI-AKI present with a high-risk pattern, CI-AKI can significantly influence late cardiovascular outcomes independent of comorbid risk factors.
These results are in agreement with a substudy of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. The CADILLAC investigators stratified 2082 patients with STEMI according to baseline creatinine clearance either >60 mL/min or ≤60 mL/min and aimed to identify the impact on survival of renal dysfunction. In this substudy, CI-AKI was found in 9.7% of patients with mild-to-moderate baseline renal insufficiency and was associated with a strikingly worse prognosis with a near 3-fold relative risk increase. 18 Our data and previous findings indicate that CI-AKI may be considered as a marker of poor long-term cardiovascular outcomes, therefore, strengthening the presence of a real cardiorenal relationship strongly influencing risk of patients undergoing PCI. 19, 20 Indeed, patients developing acute kidney injury are more likely to experience death, MI, and heart failure. [20] [21] [22] Suggested pathophysiologic mechanisms between acute kidney injury and cardiovascular events include fluid retention leading to cardiac instability and inflammation leading to apoptosis and fibrosis at the cellular level. 23, 24 However, in agreement with other reports, 3, 25 we found that although patients with cardiac dysfunction and multiple comorbidities are more susceptible to CI-AKI, this does not preclude the substantial impact of CI-AKI on outcomes of all patients undergoing PCI. One-year Kaplan-Meier curves for selected end points in patients who developed and did not develop contrast-induced acute kidney injury (CI-AKI). CI indicates confidence interval; HR, hazard ratio; MACE indicates major adverse cardiac events; MI, myocardial infarction; QWMI, Q-wave myocardial infarction; and TLR, target lesion revascularization.
Contrast-Induced AKI and Adverse Outcomes
The present study also extends earlier work evaluating associations between CI-AKI and bleeding. Levy et al 12 first described a significant prevalence of bleeding events (38%) among patients with CI-AKI, indicating this complication as main cause of in-hospital death. Later, Rihal et al 11 found a higher incidence of access-site bleeding in CI-AKI; however, this did not exclude possible confounding factors. Recently, Maioli et al 13 conducted a randomized comparison of 2 CI-AKI prevention strategies in STEMI finding a significant increase in major bleeding (10.8% versus 4.5%; P=0.04) in patients with CI-AKI. Regardless of the scale used, we found a consistent increase in major bleeding among patient who developed CI-AKI. Accordingly, rates of need for blood product transfusions and hemoglobin drop ≥4 mg/dL were significantly higher in the CI-AKI group. To minimize the possibility of reverse causality on the observed association between CI-AKI and bleeding as well as to reduce the influence of potential procedure-related events, we performed a landmark analysis starting from the third postprocedural day. Although, as expected, overall bleeding rates were reduced, the significant and incremental hazard for bleeding associated with CI-AKI persisted in this time interval. Finally, we attempted to define whether CI-AKI was independently associated with bleeding events at 30 days. After multivariate analysis, we found CI-AKI was the strongest predictor of bleeding, followed by CKD and DM. Because CKD and DM are frequently associated with CI-AKI, the increased risk conferred by CI-AKI for bleeding is probably compounded by the coexistence of CKD and DM.
A variety of causal mechanisms have been postulated to explain the increased bleeding propensity in the setting of CKD, including anomalous platelet function and aggregation, 25 altered platelet-endothelial interactions, 26, 27 unbalanced prostaglandin metabolism, 26 enhanced nitric oxide production, 28 abnormal von Willebrand factor, 29 and impaired serotonin uptake and release. 30 It is also possible that similar processes occur in the acute setting since Fox et al 31 reported that ACS patients experiencing acute kidney injury experience higher rates of major bleeding in correlation with increasing serum creatinine levels and Tsai et al 20 found that patients undergoing PCI seems to have a bleeding risk increase proportional to the degree of renal deterioration after the procedure.
Finally, Ohno et al 32 described bleeding events as a cause of CI-AKI. Indeed, bleeding events can produce hemodynamic instability and reduce hematocrit, 2 other conditions Potential covariables included in model: contrast-induced acute kidney injury, age, sex, diabetes, creatinine clearance <60 mL/min, contrast volume (per 100 mL increase), randomization to bivalirudin, randomization to glycoprotein IIb/IIIa inhibitor history of hypertension, hyperlipidemia, anemia, previous percutaneous coronary intervention, and previous coronary artery bypass grafting. CI indicates confidence interval; and HR, hazard ratio.
*Renal dysfunction was defined as estimated glomerular filtration rate <60 mL/min. that have been independently associated with CI-AKI development. 3, 11 The conclusions of Ohno et al and the findings observed in this study may suggest a bidirectional association between bleeding events and CI-AKI.
Limitations
This study is not without limitations. First, as a post hoc analysis of a prospective study, these results can only demonstrate correlation but cannot prove causation, and a strong pathophysiologic explanation for bleeding in acute kidney injury is currently missing. Moreover, being primary trials designed for other purposes, some baseline (asymptomatic left ventricular dysfunction, chronic heart failure, etc.) and periprocedural (systemic blood pressure, cystatin C, etc.) variables that could be useful for the present analysis were not available.
Second, patients who developed CI-AKI exhibited significant differences at baseline compared with patient who did not develop CI-AKI, and despite adjustment for observed covariates, we cannot completely exclude that unmeasured confounders could have influenced our results. Therefore, these findings should be considered hypothesis generating, and further studies to confirm our results are required.
Third, although landmark analysis reduced the influence of procedural-related bleeding, we cannot exclude that events occurring within the first 3 days were persisting beyond and, therefore, accounted in our sensitivity analysis.
Finally, although contrast exposure is the most likely cause for renal dysfunction in these patients, there exists the possibility for other causes, including atheroembolic and prerenal AKI.
Conclusions
CI-AKI is a major complication after PCI for ACS and confers a substantial and increased risk for morbidity and mortality in the short and long term. Even after multivariable adjustment, CI-AKI remained a strong and independent predictor of adverse cardiovascular outcomes at 1 year. Finally, the present investigation demonstrates a strong association between CI-AKI and 30-day bleeding risk, highlighting the morbidity for both ischemic and hemorrhagic complications associated with CI-AKI.
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